Annual EBITDA
-$143.20 M
+$8.45 M+5.57%
31 December 2023
Summary:
Kymera Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$143.20 million, with the most recent change of +$8.45 million (+5.57%) on 31 December 2023. During the last 3 years, it has fallen by -$99.49 million (-227.58%). KYMR annual EBITDA is now -574.01% below its all-time high of -$21.25 million, reached on 31 December 2018.KYMR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$60.44 M
-$20.38 M-50.86%
30 September 2024
Summary:
Kymera Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$60.44 million, with the most recent change of -$20.38 million (-50.86%) on 30 September 2024. Over the past year, it has dropped by -$8.51 million (-16.39%). KYMR quarterly EBITDA is now -709.32% below its all-time high of -$7.47 million, reached on 30 September 2020.KYMR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$160.96 M
-$8.51 M-5.58%
30 September 2024
Summary:
Kymera Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$160.96 million, with the most recent change of -$8.51 million (-5.58%) on 30 September 2024. Over the past year, it has increased by +$2.81 million (+1.72%). KYMR TTM EBITDA is now -1329.69% below its all-time high of -$11.26 million, reached on 30 September 2019.KYMR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
KYMR EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +5.6% | -16.4% | +1.7% |
| 3 y3 years | -227.6% | -117.1% | -110.0% |
| 5 y5 years | -574.0% | -436.9% | -1329.7% |
KYMR EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -227.6% | +5.6% | -350.2% | at low | -110.0% | +1.7% |
| 5 y | 5 years | -574.0% | +5.6% | -709.3% | at low | -1329.7% | +1.7% |
| alltime | all time | -574.0% | +5.6% | -709.3% | at low | -1329.7% | +1.7% |
Kymera Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$60.44 M(+50.9%) | -$160.96 M(+5.6%) |
| June 2024 | - | -$40.06 M(-14.8%) | -$152.45 M(+1.5%) |
| Mar 2024 | - | -$47.03 M(+250.3%) | -$150.23 M(+4.9%) |
| Dec 2023 | -$143.20 M(-5.6%) | -$13.43 M(-74.1%) | -$143.20 M(-12.6%) |
| Sept 2023 | - | -$51.93 M(+37.2%) | -$163.76 M(+6.3%) |
| June 2023 | - | -$37.85 M(-5.4%) | -$154.03 M(-1.1%) |
| Mar 2023 | - | -$39.99 M(+17.7%) | -$155.69 M(+2.7%) |
| Dec 2022 | -$151.66 M(+55.3%) | -$33.99 M(-19.5%) | -$151.65 M(+0.5%) |
| Sept 2022 | - | -$42.20 M(+6.8%) | -$150.83 M(+10.5%) |
| June 2022 | - | -$39.51 M(+9.9%) | -$136.47 M(+12.7%) |
| Mar 2022 | - | -$35.96 M(+8.4%) | -$121.04 M(+24.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$97.64 M(+123.4%) | -$33.16 M(+19.1%) | -$97.65 M(+27.4%) |
| Sept 2021 | - | -$27.84 M(+15.6%) | -$76.65 M(+36.2%) |
| June 2021 | - | -$24.08 M(+91.6%) | -$56.27 M(+23.0%) |
| Mar 2021 | - | -$12.57 M(+3.3%) | -$45.77 M(+4.7%) |
| Dec 2020 | -$43.72 M(+8.3%) | -$12.16 M(+62.8%) | -$43.72 M(+2.4%) |
| Sept 2020 | - | -$7.47 M(-45.0%) | -$42.68 M(-8.2%) |
| June 2020 | - | -$13.57 M(+29.2%) | -$46.47 M(+41.3%) |
| Mar 2020 | - | -$10.51 M(-5.5%) | -$32.89 M(+47.0%) |
| Dec 2019 | -$40.38 M(+90.0%) | -$11.12 M(-1.2%) | -$22.38 M(+98.8%) |
| Sept 2019 | - | -$11.26 M | -$11.26 M |
| Dec 2018 | -$21.25 M | - | - |
FAQ
- What is Kymera Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Kymera Therapeutics?
- What is Kymera Therapeutics annual EBITDA year-on-year change?
- What is Kymera Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Kymera Therapeutics?
- What is Kymera Therapeutics quarterly EBITDA year-on-year change?
- What is Kymera Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Kymera Therapeutics?
- What is Kymera Therapeutics TTM EBITDA year-on-year change?
What is Kymera Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of KYMR is -$143.20 M
What is the all time high annual EBITDA for Kymera Therapeutics?
Kymera Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$21.25 M
What is Kymera Therapeutics annual EBITDA year-on-year change?
Over the past year, KYMR annual earnings before interest, taxes, depreciation & amortization has changed by +$8.45 M (+5.57%)
What is Kymera Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of KYMR is -$60.44 M
What is the all time high quarterly EBITDA for Kymera Therapeutics?
Kymera Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$7.47 M
What is Kymera Therapeutics quarterly EBITDA year-on-year change?
Over the past year, KYMR quarterly earnings before interest, taxes, depreciation & amortization has changed by -$8.51 M (-16.39%)
What is Kymera Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of KYMR is -$160.96 M
What is the all time high TTM EBITDA for Kymera Therapeutics?
Kymera Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$11.26 M
What is Kymera Therapeutics TTM EBITDA year-on-year change?
Over the past year, KYMR TTM earnings before interest, taxes, depreciation & amortization has changed by +$2.81 M (+1.72%)